Commercialization, regulatory, and fundraising strategy for an academic research group taking a validated clinical diagnostic technology from published research toward market entry.
Academic Research Group
8/4/2024
An academic group with substantial publications and clinical validation needed to turn its diagnostic technology into a company: a market entry path, a regulatory route, the right industry partners, and materials credible enough to raise on.
A strategic engagement covering market and competitive analysis, go-to-market design, FDA pathway planning, partner identification, and preparation of investor materials and financial models.
Engagement
Regulatory
Output
Fundraising
An academic research group with substantial publications and clinical validation behind it wanted to get its diagnostic technology into the hands of clinics: reliably, affordably, and at a scale academic research alone would never reach.
That is a different problem from the one they had already solved. The science was done. What was missing was a route to market, a regulatory path, and the case that would persuade partners and investors to back it.
Client: An academic research group with published clinical validation of its technology.
Engagement: Commercialization strategy, regulatory planning, partner identification, and investor readiness.
We quantified the market opportunity, identified the customer segments worth pursuing first, and assessed the competitive set to establish where the technology was genuinely differentiated. Trends that bore directly on adoption, including telehealth, clinical AI, and the shift toward value-based care, were assessed for how they would affect the timing of market entry.
We designed a multi-pronged approach spanning licensing, direct sales, and partnerships, with the pricing, distribution, and marketing plans each route would require. For a research group without commercial infrastructure, the choice among these is largely a question of what they can realistically execute, not what returns most in theory.
We mapped the FDA pathway, including 510(k) for Class II devices, and set out the clinical data required to support a submission. Planning also covered HIPAA and data security obligations, and the CPT coding and insurance inclusion work that determines whether a cleared device actually gets reimbursed.
We identified target partners across manufacturers, EHR providers, and academic centers, and built the frameworks for approaching them. Alongside this we produced financial projections and the investor materials the group would need to raise.
We documented market, financial, technical, operational, and regulatory risks with mitigations for each, on the basis that investors and partners will find them regardless, and it is better to have already thought them through.
The group came out with a commercialization and regulatory strategy specific enough to act on: a business plan, market entry tactics, an FDA pathway with its clinical data requirements, partner engagement frameworks, investor materials and financial models, and a documented risk register.
The engagement simplified the immediate regulatory burden, gave the technical team a clear plan to work against, and produced a defined beachhead to present to partners and investors.
Client identity and technology details are withheld under confidentiality.
